This is an amended filing
Disclosure
RCommentary
AI commentary · Not investment advice
What happened
Yi Yeon Pharmaceutical (Daewoong-affiliated peers aside, this is the company named in the filing) reported the issuance of convertible bonds in a material-matters report filed on 2026.10.27. The face value is KRW 9.0 billion, the payment date is 2026.10.28, and the maturity date is 2031.10.28. The proceeds are for operating funds. The conversion price is KRW 10,000, and conversion would produce 884,955 new shares.
In the company's terms
Relative to the company, the issue equals 5.0% of market capitalization. The shares to be issued on conversion are 4.54% of total shares. The materials also give a ratio of convertible shares to shares already issued of 49.15%. There was 1 disclosure of the same type in the past year, and a prior disclosure dated 2026.10.26.
What changes for shareholders
For shareholders, if the bonds are converted, the number of shares could increase by 884,955, which is 4.54% of total shares. The bonds also carry a call option of 20%, under which the company could acquire up to KRW 1.8 billion.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist